[Composition and distribution of zooplankton species in the subtropical areas of the Northwestern Pacific Ocean]. / 西北太平洋亚热带海域浮游动物种类组成与分布.

Based on the investigation data of 44 stations in the area 28°ï¼35° N, 147°ï¼154° E of the Northwestern Pacific Ocean by the research ship 'Songhang' in March 2019, we analyzed species composition and distribution of zooplankton to understand zooplankton community structure in the subtropical areas of the Northwestern Pacific Ocean. The results showed that a total of 456 zooplankton species (including planktonic larvae and unidentified species) were recorded in the surveyed area, which were belonged to 8 categories and 14 groups. There were 163 species of copepods, as the dominant group. The dominant species included 9 warm-water species, Eudoxoides spiralis, Neocalanus gracilis, Pleuromamma gracilis, Sagitta enflata, Doliolum nationalis, S. hexaptera, Euchirella rostrata, Nannocalanus minor and Mesocalanus tenuicornis, and one temperate species, Calanus jashnovi. Both the warm current indicator species S. hexaptera and the cold current indicator species C. jashnovi occurred simultaneously in the subtropical area, indicating that the Kuroshio Current and the Oyashio Current had an important impact on the diversity and temporal-spatial distribution of marine zooplankton. The average biomass was (31.64±23.81) mg·m-3, and the average abundance was (22.2±17.6) ind·m-3. The average values of purity index (C), eveness index (J), Shannon diversity index (H) and richness index (D) were 0.09±0.10, 0.76±0.10, 4.88±0.71, and 23.53±8.08, respectively. The spatial distribution of the four indices were uneven and irregular. During the study period, species composition of zooplankton in the Northwest Pacific was rich, species distribution was uneven, and community structure was stable.

[Preliminary analysis on the composition of fish and cephalopod in diet of Dosidicus gigas in the high sea of Eastern Pacific Ocean]. / ä¸œå¤ªå¹³æ´‹å ¬æµ·èŒŽæŸ”é±¼é¥µæ–™ä¸­é±¼ç±»å’Œå¤´è¶³ç±»ç»„æˆåˆæ­¥åˆ†æž.

Dosidicus gigas is widely distributed in the Eastern Pacific Ocean and plays an important role in the marine ecosystem. In this study, we identified and analyzed 4131 otoliths and 75 beaks from the stomach content residuals of 62 D. gigas samples, which were collected by Chinese squid jigging vessels in the high sea of Eastern Pacific Ocean from June to December 2019. The results showed that the preys of D. gigas included 10 fish species and 4 cephalopod species. Judging from the frequency of appearance and percentage of amount, Vinciguerria lucetia, Diogenichthys laternatus, and Triphoturus mexicanus were the dominant myctophidae prey of D. gigas. Among those preys, V. lucetia was the most important one, as it was found in all D. gigas with different mantle lengths. D. gigas, Sthenoteuthis oualaniensis, and Onychoteuthis banksii were the dominant cephalopod prey. With the growth of mantle length of D. gigas, the number of prey species, the percentage of cephalopod and myctophidae preys, and the size of preys increased, and thus the trophic level of preys increased as the trophic pattern of preys changed. Our results could provide basic information for evaluating the contribution of different preys in the preying transformation of D. gigas.

Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.

INTRODUCTION: The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial. No meta-analysis has been written to discuss this from the prospective interventional studies. The objective was to evaluate the association between the use of incretins and fracture risk. MATERIAL AND METHODS: Multiple databases were searched for original articles that investigated the relationship between the use of incretin agents and fracture risk, up to December 2019. Trials using the Mantel-Haenszel method to calculate OR and 95% CI were pooled. The multiple sensitivity, heterogeneity, publication bias, and quality were analysed among the studies to evaluate the robustness of results. RESULTS: The fixed-effects model was used on account of the I² test for heterogeneity (I² = 0.0%). Incretins were not associated with fracture risk [0.97 (95% CI: 0.88-1.08)]. But in the subgroup analysis, when sitagliptin 100 mg per day (OR 0.495, 95% CI: 0.304-0.806) or liraglutide 1.8 mg per day was administered (OR 0.621, 95% CI: 0.413-0.933), it reduced fracture risk. The sensitivity analysis and publication bias prompted the robustness of results. CONCLUSIONS: This meta-analysis suggested that the current use of incretins not only is safe for fracture in type 2 diabetes patients from RCT studies, but also, when sitagliptin 100 mg or liraglutide 1.8 mg per day was administered, it may exhibit protective effects on bone metabolism.

[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets].

OBJECTIVE: To study the pharmacokinetics and relative bioavailability of neostigmine bromide conventional tablets and sustained-release tablets in rabbits. METHODS: Six healthy rabbits were randomly divided into two groups for a cross self-contrast trial. RP-HPLC was used to detect plasma concentrations of neostigmine bromide. The pharmacokinetic parameters were calculated with the aid of DAS 2.0 software. RESULTS: The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h. The relative bioavailability of the neostigmine bromide sustained-release tablets was 115.4%. CONCLUSION: The pharmacokinetics of neostigmine bromide accords with two compartments model, showing constant plasma concentration and relatively high bioavailability.

[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system].

OBJECTIVE: To establish an high-performance liquid chromatography (HPLC)-based method for analysis of the pharmacokinetics and relative bioavailability of dextromethorphan chewing gum tablets in rabbits. METHODS: The pharmacokinetic parameters and the relative bioavailability of dextromethorphan chewing gum preparation in rabbits were compared with those of the commercially available chewing dextromethorphan tablets using 3P97 software. RESULTS: Pharmacokinetic analysis of the new dextromethorphan chewing gum tablets showed a AUC of 488.76 ∓ 175.00 ng.ml(-1).h, C(max) of 95.45 ∓ 17.53 ng/ml, and t(max) of 1.83 ∓ 0.57 h as compared with the corresponding parameters of 370.13 ∓ 90.56 ng.ml(-1).h, 174.00 ∓ 47.88 ng.ml, and 1.04 ∓ 0.14 h for the commercially available chewing tablets. The relative bioavailability of the new chewing gum medicine system was (140.73 ∓ 65.91)%. CONCLUSION: The new dextromethorphan chewing gum preparation shows an increased AUC((0→)), decreased C(max), and prolonged t(max) in comparison with the commercially available chewing tablets, with also a greatly enhanced relative bioavailability.